Sign in

    Parth Patel • Morgan Stanley

    Parth Patel's questions to Axsome Therapeutics Inc (AXSM) leadership

    Parth Patel's questions to Axsome Therapeutics Inc (AXSM) leadership • Q1 2025

    Question

    Parth Patel, on behalf of Vikram Purohit from Morgan Stanley, asked about the intended design of the upcoming Phase III trial for solriamfetol in MDD with EDS, including study size and key endpoints, and whether this would be the sole additional trial required for a potential filing.

    Answer

    Herriot Tabuteau, CEO, responded that specific study designs are disclosed upon trial launch. He noted that the design will incorporate learnings from the recently completed proof-of-concept study. He highlighted that the target population of MDD with excessive sleepiness represents about 50% of all MDD patients but did not specify if this would be the only trial needed for approval.

    Ask Fintool Equity Research AI

    Parth Patel's questions to Kymera Therapeutics Inc (KYMR) leadership

    Parth Patel's questions to Kymera Therapeutics Inc (KYMR) leadership • Q4 2024

    Question

    Parth Patel from Morgan Stanley asked about the potential scope of the Phase III development program for KT-621 and how Kymera would prioritize among the broad potential indications.

    Answer

    CEO Nello Mainolfi stated the plan balances speed and breadth, with the Phase IIb studies informing dose selection for up to eight indications. He expects to prioritize atopic dermatitis and asthma, which are major markets for dupilumab, and likely COPD, before deciding on parallel or staggered development for other indications.

    Ask Fintool Equity Research AI